Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Knop

Showing results (141-150 of 509) with videos related to

Pageof 51
Sort By:
The Journal of Clinical Endocrinology and Metabolism|April 23, 2010
Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjectsK B Hansen, T Vilsbøll, J I Bagger, et al.
European Journal of Endocrinology|July 3, 2014
Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1David P Sonne, Jens F Rehfeld, Jens J Holst, et al.
Frontiers in Endocrinology|November 22, 2018
Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLDMarta Seghieri, Alexander S Christensen, Andreas Andersen, et al.
Diabetes Care|August 28, 2003
No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitisFilip K Knop, Tina Vilsbøll, Steen Larsen, et al.
Journal of Internal Medicine|July 16, 2015
Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasisM Gyldenløve, T Vilsbøll, C Zachariae, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 21, 2016
Use of antibiotics in childhood and risk of Type 1 diabetes: a population-based case-control studyK H Mikkelsen, F K Knop, T Vilsbøll, et al.
Regulatory Peptides|June 25, 2010
Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitisF K Knop, T Vilsbøll, S Larsen, et al.
BMJ Open|October 6, 2018
Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trialAlexander Sidelmann Christensen, Heidi Storgaard, Sofie Hædersdal, et al.
Journal of the American Academy of Dermatology|February 6, 2015
Patients with psoriasis are insulin resistantMette Gyldenløve, Heidi Storgaard, Jens J Holst, et al.
The British Journal of Dermatology|March 31, 2015
Disturbed postprandial glucose metabolism and gut hormone responses in non-diabetic patients with psoriasisM Gyldenløve, T Vilsbøll, J J Holst, et al.
Pageof 51

Showing results (141-150 of 509) with videos related to

Sort By:
Pageof 51
The Journal of Clinical Endocrinology and Metabolism|April 23, 2010
Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjectsK B Hansen, T Vilsbøll, J I Bagger, et al.
European Journal of Endocrinology|July 3, 2014
Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1David P Sonne, Jens F Rehfeld, Jens J Holst, et al.
Frontiers in Endocrinology|November 22, 2018
Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLDMarta Seghieri, Alexander S Christensen, Andreas Andersen, et al.
Diabetes Care|August 28, 2003
No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitisFilip K Knop, Tina Vilsbøll, Steen Larsen, et al.
Journal of Internal Medicine|July 16, 2015
Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasisM Gyldenløve, T Vilsbøll, C Zachariae, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 21, 2016
Use of antibiotics in childhood and risk of Type 1 diabetes: a population-based case-control studyK H Mikkelsen, F K Knop, T Vilsbøll, et al.
Regulatory Peptides|June 25, 2010
Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitisF K Knop, T Vilsbøll, S Larsen, et al.
BMJ Open|October 6, 2018
Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trialAlexander Sidelmann Christensen, Heidi Storgaard, Sofie Hædersdal, et al.
Journal of the American Academy of Dermatology|February 6, 2015
Patients with psoriasis are insulin resistantMette Gyldenløve, Heidi Storgaard, Jens J Holst, et al.
The British Journal of Dermatology|March 31, 2015
Disturbed postprandial glucose metabolism and gut hormone responses in non-diabetic patients with psoriasisM Gyldenløve, T Vilsbøll, J J Holst, et al.
Pageof 51